Recent early clinical drug development for acute kidney injury

Kevin Gallagher, Stephen O'neill, Ewen M Harrison, James A Ross, Stephen J Wigmore, Jeremy Hughes

Research output: Contribution to journalLiterature reviewpeer-review

Abstract / Description of output

Introduction: Despite significant need and historical trials, there are no effective drugs in use for the prevention or treatment of acute kidney injury (AKI). There are several promising agents in early clinical development for AKI and two trials have recently been terminated. There are also exciting new findings in pre-clinical AKI research. There is a need to take stock of current progress in the field to guide future drug development for AKI.

Areas covered: The main clinical trial registries, PubMed and pharmaceutical company website searches were used to extract the most recent clinical trials for sterile, transplant and sepsis-associated AKI. We summarise the development of the agents recently in clinical trial, update on their trial progress, consider reasons for failed efficacy of two agents, and discuss new paradigms in pre-clinical targets for AKI. Agents covered include- QPI-1002, THR-184, BB-3, heme arginate, human recombinant alkaline phosphatase (recAP), ciclosporin A, AB103, levosimendan, AC607 and ABT-719.

Expert Opinion: Due to the heterogenous nature of AKI, agents with the widest pleiotropic effects on multiple pathophysiological pathways are likely to be most effective. Linking preclinical models to clinical indication and improving AKI definition and diagnosis are key areas for improvement in future clinical trials.
Key words: Acute kidney injury, alkaline phosphatase, α-melanocortin receptor 1, bone morphogenetic protein receptor, cardiac surgery AKI, delayed graft function, hepatocyte growth factor, p53, sepsis associated AKI
Original languageEnglish
JournalExpert opinion on investigational drugs
Early online date20 Dec 2016
Publication statusE-pub ahead of print - 20 Dec 2016


Dive into the research topics of 'Recent early clinical drug development for acute kidney injury'. Together they form a unique fingerprint.

Cite this